NCT02975999View on ClinicalTrials.gov

Use of Vasopressin Following the Fontan Operation

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Pleural EffusionSingle-ventricle
Interventions
DRUG

Vasopressin

Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.

DRUG

Normal Saline

Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.

Trial Locations (1)

60453

Advocate Children's Hospital, Oak Lawn

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER

NCT02975999 - Use of Vasopressin Following the Fontan Operation | Biotech Hunter | Biotech Hunter